BENZOIC ACID SALT OF OTAMIXABAN

BENZOIC ACID SALT OF OTAMIXABAN

The invention relates to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino (imino) methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate, and to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxidopyridin-4- yl)benzoyl]amino}butanoate which is in a crys...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BAUMGARTNER, BRUNO, AYERS, TIMOTHY, NAGEL, NORBERT, BERCHTOLD, HARALD
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino (imino) methyl]benzyl}-3-{[4-(1 -oxidopyridin-4-yl)benzoyl]amino}butanoate, and to a benzoic acid salt of methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1 -oxidopyridin-4- yl)benzoyl]amino}butanoate which is in a crystalline form or in at least partially crystalline form, as well as a process for the preparation of the same, methods of using such salt to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa. L'invention concerne un sel d'acide benzoïque de (2R,3R)-2-{3-[amino (imino)méthyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate de méthyle, et un sel d'acide benzoïque de (2R,3R)-2-{3-[amino(imino)méthyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate de méthyle qui est sous une forme cristalline ou sous une forme au moins partiellement cristalline, ainsi qu'un procédé pour la préparation des mêmes, les procédés d'utilisation d'un tel sel pour traiter des sujets souffrant de pathologies qui peuvent être améliorées par l'administration d'un inhibiteur du Factor Xa.